We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is partnering with the Massachusetts Institute of Technology (MIT) to develop new databases to monitor devices and drugs after they have been approved. But one critic says databases aren’t the solution to improving postmarket surveillance.
The FDA announced last week it has entered into a three-year agreement with two national institutions to facilitate the development and regulation of nanotechnologies for research and cancer treatments, but one critic asserts the agency also needs to take similar actions for OTC products.
The FDA is partnering with the Massachusetts Institute of Technology (MIT) to develop new databases as part of a broad agency initiative to improve its postapproval monitoring of drugs, a high-ranking FDA official said.
Clinical research sites would benefit greatly from across-the-board adoption of data standards, according to experts who spoke at a recent industry conference.
Wyeth Pharmaceuticals is expanding its esubmission program and capabilities working with Octagon Research Solutions, Octagon President Kirk Gallion told PIR Aug. 11.
IBM last week unveiled a radio-frequency identification (RFID) system for tracking and tracing pharmaceuticals. The system is designed to make it more difficult for counterfeit drugs to get to market, the company said.
Electronic data capture (EDC) in clinical trials offers a host of benefits for sponsors if done properly, an expert said at a recent FDAnews audioconference.
Storage virtualization has entered the mainstream of operations for many large companies and will expand greatly within the next 12 months, says a new white paper by IDC analysts.
NextNine, provider of automated, remote service and support solutions, just announced the successful deployment of Allscripts’ new proactive service platform, SupportOne, which is based on NextNine Service Automation (NSA) software.
Buoyed in part by moves from big pharmaceutical firms and the broader Signatures and Authentication for Everyone (SAFE) movement, public key infrastructure (PKI) will increasingly play an important part in edata security solutions for FDA-regulated life sciences firms, Cybertrust Vice President Tom Greco told PIR last week.